AC
PCRX icon

Aristeia Capital’s Pacira BioSciences PCRX Stock Holding History

Aristeia Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-64,800
Closed -$2.96M – 50
2017
Q4 		$2.96M Sell
64,800
-30,000
-32% -$1.19M 0.13% 40
2017
Q3 		$3.56M Sell
94,800
-47,800
-34% -$1.92M 0.14% 38
2017
Q2 		$6.8M Buy
142,600
+27,600
+24% +$1.28M 0.33% 33
2017
Q1 		$5.24M Buy
+115,000
New +$4.97M 0.41% 35

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Aristeia Capital's PCRX Position: Q1 2018 in Review

Aristeia Capital sold out of Pacira BioSciences (PCRX) in Q1 2018, closing a stake of 64,800 shares — an estimated $2.96M sold.

Aristeia Capital first reported a position in PCRX in Q1 2017 and held it in 4 quarters. The position peaked at $6.8M in Q2 2017. 168 funds tracked by Wall St. Rank hold PCRX as of Q1 2018.

  • Aristeia Capital reported no remaining Pacira BioSciences position as of Q1 2018 after selling out during the quarter.
  • Aristeia Capital sold 64,800 Pacira BioSciences shares in Q1 2018, an estimated $2.96M.
  • Aristeia Capital first reported a position in Pacira BioSciences in Q1 2017 and held it in 4 quarters.
  • Aristeia Capital's Pacira BioSciences position peaked at $6.8M in Q2 2017.
  • 168 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2018.

Based on Aristeia Capital's 13F filing for Q1 2018, filed 15 May 2018.